The ASCO Annual Meeting begins on June 4, and here is some of the notable research that will be presented. Topics include combined immunotherapy for esophageal cancer, targeted radiation for mCRPC, olaparib for HER2-negative breast cancer, adjuvant chemotherapy for cervical cancer, pembrolizumab for kidney cancer, and toripalimab for nasopharyngeal cancer.

Lea los puntos destacados de la investigación temprana que acaban de publicar para la reunión anual de la American Society of Clinical Oncology (Sociedad Americana de Oncología Clínica) de 2021. Los temas incluyen la inmunoterapia para el melanoma y el cáncer de pulmón de no microcítico (NSCLC, por sus siglas en inglés), la detección del antígeno prostático específico (PSA, por sus siglas en inglés) para el cáncer de próstata, la vacunación contra el VPH y los límites de elegibilidad de los ingresos de Medicaid.

Read early research highlights just released for the 2021 ASCO Annual Meeting. Topics include immunotherapy for melanoma and non-small cell lung cancer, PSA screening for prostate cancer, HPV vaccination, and Medicaid income eligibility limits.

Learn more about research presented at the 2021 Genitourinary Cancers Symposium, including immunotherapy for people with high-risk bladder cancer and a link between less PSA screening and diagnoses of metastatic prostate cancer.

ASCO’s 2021 Advance of the Year highlights how progress in the treatment of gastrointestinal (GI) cancers is driven by molecular testing of tumors.

Dr. Neeraj Agarwal discusses 3 clinical trials presented at the 2020 ESMO Virtual Congress that studied new treatments for advanced kidney cancer, prostate cancer, and bladder cancer.

Can immunotherapy be used to treat breast cancer? This expert Q&A explains.

In this podcast, Cancer.Net Associate Editors share exciting research from the ASCO20 Virtual Scientific Program.

Read research highlights just released from the ASCO20 Virtual Scientific Program. They include studies on immunotherapy for metastatic colorectal cancer and gestational trophoblastic disease, maintenance therapy for advanced bladder cancer, the potential of precision medicine for childhood cancers, and targeted therapy after surgery for EGFR-positive non-small cell lung cancer.

Lea los puntos destacados de la investigación del programa científico virtual ASCO20 que se acaban de publicar. Incluyen estudios sobre inmunoterapia para el cáncer colorrectal metastásico y la enfermedad trofoblástica gestacional, terapia de mantenimiento para el cáncer de vejiga avanzado, el potencial de la medicina de precisión para el cáncer infantil y la terapia dirigida después de la cirugía por EGFR (receptor del factor de crecimiento epidérmico), positivo de cáncer de pulmón de células no pequeñas.